Table 1 Demographic and clinical characteristics at baseline
| Â | Total population |
|---|---|
| Â | n = 250 |
Demographics | Â |
Age, years | 52 ± 13 |
Female, no. (%) | 197 (79) |
DMARD therapy | Â |
Prior DMARDs (no.) | 3.4 ± 1.6 |
Methotrexate use, no. (%) | 199 (80) |
Methotrexate dose (mg/wk) | 23 (15 to 25) |
Prednisone use, no. (%) | 82 (33%) |
Prednisone dose (mg/day) | 7.5 (5 to 10) |
Disease status | Â |
Disease duration (years) | 8 (4 to 17) |
Rheumatoid factor positive, no. (%) | 179 (72) |
Erosive disease, no. (%) | 194 (78) |
Erythrocyte sedimentation rate (mm/h) | 30 ± 23 |
C-reactive protein (mg/dl) | 11 (5 to 24) |
DAS28 | 5.2 ± 1.2 |